Vivos Therapeutics, Inc.

NasdaqCM VVOS

Vivos Therapeutics, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 2.04

Vivos Therapeutics, Inc. Price to Sales Ratio (P/S) is 2.04 on January 14, 2025, a 133.51% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Vivos Therapeutics, Inc. 52-week high Price to Sales Ratio (P/S) is 2.05 on January 10, 2025, which is 0.40% above the current Price to Sales Ratio (P/S).
Vivos Therapeutics, Inc. 52-week low Price to Sales Ratio (P/S) is 0.34 on May 30, 2024, which is -83.15% below the current Price to Sales Ratio (P/S).
Vivos Therapeutics, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 0.82.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqCM: VVOS

Vivos Therapeutics, Inc.

CEO	Mr. R. Kirk Huntsman
IPO Date	Dec. 11, 2020
Location	United States
Headquarters	9137 Ridgeline Boulevard
Employees	114
Sector	Health Care
Industries Pharmaceuticals Clinical Trials Dental Care Telehealth

Description

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.

Key trends

Past 5 years